Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fierz

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Nature|April 9, 1981
Supposed lamarckian inheritance of immunological toleranceL Brent, L S Rayfield, P Chandler, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Suppression of P2-T-cell line mediated experimental autoimmune neuritis by interleukin-2 receptor blockadeH P Hartung, B Schäfer, T Diamantstein, et al.
Annals of Neurology|April 1, 1988
The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell lineK Heininger, B Schäfer, H P Hartung, et al.
Nature|January 21, 1982
Further studies on supposed lamarckian inheritance of immunological toleranceL Brent, P Chandler, W Fierz, et al.
Schweizerische Medizinische Wochenschrift|November 13, 1976
[The Sézary syndrome]C Maier, W Fierz, W Goor, et al.
Klinische Wochenschrift|April 17, 1990
[The effect of rejection crises and immunosuppressive therapy on the lymphocyte subpopulations of patients after kidney transplantation]A v Kiparski, D Frei, W Fierz, et al.
Dermatologica|January 1, 1979
The Sézary syndromeW Goor, C Maier, W Fierz, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|June 1, 1996
Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutionsJ Schilling, N Vranjes, W Fierz, et al.
Schweizerische Medizinische Wochenschrift|January 16, 1988
[HIV serological parameters in the prognosis and follow-up assessment of an HIV infection]P J Grob, H Joller-Jemelka, R Lüthy, et al.
Journal of Neuroimmunology|May 15, 2007
Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapiesR Gold, A Jawad, D H Miller, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Nature|April 9, 1981
Supposed lamarckian inheritance of immunological toleranceL Brent, L S Rayfield, P Chandler, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Suppression of P2-T-cell line mediated experimental autoimmune neuritis by interleukin-2 receptor blockadeH P Hartung, B Schäfer, T Diamantstein, et al.
Annals of Neurology|April 1, 1988
The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell lineK Heininger, B Schäfer, H P Hartung, et al.
Nature|January 21, 1982
Further studies on supposed lamarckian inheritance of immunological toleranceL Brent, P Chandler, W Fierz, et al.
Schweizerische Medizinische Wochenschrift|November 13, 1976
[The Sézary syndrome]C Maier, W Fierz, W Goor, et al.
Klinische Wochenschrift|April 17, 1990
[The effect of rejection crises and immunosuppressive therapy on the lymphocyte subpopulations of patients after kidney transplantation]A v Kiparski, D Frei, W Fierz, et al.
Dermatologica|January 1, 1979
The Sézary syndromeW Goor, C Maier, W Fierz, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|June 1, 1996
Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutionsJ Schilling, N Vranjes, W Fierz, et al.
Schweizerische Medizinische Wochenschrift|January 16, 1988
[HIV serological parameters in the prognosis and follow-up assessment of an HIV infection]P J Grob, H Joller-Jemelka, R Lüthy, et al.
Journal of Neuroimmunology|May 15, 2007
Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapiesR Gold, A Jawad, D H Miller, et al.
Pageof 7